---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-079165"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:22:13.339445+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy

## Summary
- Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.
- Patients pre-screened using DRP companion diagnostic; show durable clinical benefit in heavily pre-treated population.
- One confirmed complete response and long-term disease stability observed.
- CEO notes extending life by 52 weeks is noteworthy for heavily pre-treated patients.
- Company planning next phase of development, accelerating path toward regulatory approval.

## SEC filing metadata
- accession: 0001213900-24-079165
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/0001213900-24-079165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/ea021470501-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-079165
- JSON: https://secwatch.observer/filing/0001213900-24-079165.json
- Plain text: https://secwatch.observer/filing/0001213900-24-079165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.